Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403441 | 0.86 | MME (0.33) | ITGB1ITGA4BIRC2TAS1R3TAS1R1 | |
| SCHEMBL2462316 | 0.85 | ITGB1 (0.43) | ITGB1ITGA4TAS1R3TAS1R1CYP2C9 | |
| SCHEMBL2467566 | 0.83 | NAALAD2 (0.42) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL2467196 | 0.78 | — | — | |
| SCHEMBL29716049 | 0.76 | TGFBR1 (0.50) | ITGB1ITGA4ALDH1A1 | |
| SCHEMBL2460399 | 0.75 | ITGB1 (0.42) | ITGB1ITGA4BIRC2TAS1R3TAS1R1 | |
| SCHEMBL14693834 | 0.74 | ITGB1 (0.46) | ITGB1ITGA4BIRC2L3MBTL1CYP2C9 | |
| SCHEMBL14693833 | 0.74 | ITGB1 (0.46) | ITGB1ITGA4BIRC2L3MBTL1CYP2C9 | |
| SCHEMBL2408947 | 0.73 | ITGB1 (0.48) | ITGB1ITGA4ALDH1A1THRB | |
| SCHEMBL2873174 | 0.73 | ITGB1 (0.48) | ITGB1ITGA4ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | ITGB1 4529/4885ITGA4 4423/4885BIRC2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.